745018-39-7

Upstream product

• 56-23-5 tetrachloromethane 
• 121124-94-5 2-benzyloxy-5-bromobenzaldehyde 
• 100-39-0 benzyl bromide 
• 1761-61-1 5-bromosalicyclaldehyde 

Downstream Products

• 745018-45-5 4-benzyloxy-3-{1-[5-((2S,6R)-2,6-dimethylpiperidin-1-yl)pentyl]-3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-2-yl}benzonitrile 
• 745018-44-4 4-benzyloxy-3-[4-(5-bromopentyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-2-yl]benzonitrile 
• 745018-42-2 4-benzyloxy-3-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-2-yl)benzonitrile 
• 745018-40-0 2-(2-benzyloxy-5-bromophenyl)-4H-benzo[1,4]thiazin-3-one 

Relevant academic research and scientific papers

Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa

Factor Xa (FXa) has materialized as a key enzyme for the intervention of the blood coagulation cascade and for the development of new antithrombotic agents. FXa is the lone enzyme responsible for the production of thrombin and therefore is an attractive t

Benzoxazinoes/benzothiazinones as serine protease inhibitors

This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disease states in mammals characterized by abnornal thrombosis.